CALIFORNIA LIFE SCIENCES for CALIFORNIA LIFE SCIENCES
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Labor/HHS/Ed Appropriations: NIH, biodefense/pandemic, science/math education, and strategic stockpile funding and preparation; FDA Appropriations; PTO Appropriations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER NIETO CAREY | — |
| MEGHAN DRENAN | — |
| TODD E GILLENWATER | — |
Medical/Disease Research/Clinical Labs MED
Support NIH research funding. Support implementation of 21st Century Cures Act. Support legislation to improve medical device facility inspections processes. Support Advancing Breakthrough Medical Devices for Patients Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER NIETO CAREY | — |
| MEGHAN DRENAN | — |
| TODD E GILLENWATER | — |
Taxation/Internal Revenue Code TAX
Support repeal of medical device tax. Support extension of R&D tax credit. Oppose repeal of Orphan Drug Tax Credit. Support extension of biofuel and biodiesel tax credits.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER NIETO CAREY | — |
| MEGHAN DRENAN | — |
| TODD E GILLENWATER | — |
Copyright/Patent/Trademark CPT
Address concerns with provisions of patent litigation reform, including inter partes review. Educate on Bayh-Dole Act "march-in" provision.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER NIETO CAREY | — |
| MEGHAN DRENAN | — |
| TODD E GILLENWATER | — |
Health Issues HCR
FDA review process consistency and predictability. Address concerns with Medicare Independent Payment Advisory Board (IPAB). Address concerns with changes to Medicare Part B and Part D programs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER NIETO CAREY | — |
| MEGHAN DRENAN | — |
| TODD E GILLENWATER | — |
Medicare/Medicaid MMM
Address concerns with Medicare Independent Payment Advisory Board (IPAB). Address concerns with changes to Medicare Part B and Part D programs, and Hospital Outpatient Prospective Payment System. Address concerns with Medicaid coverage of specialty drugs. Support creation of incentives for antibiotics development. Oppose changes to Medicare Advantage and Part D prescription drug benefit. Support the Ensuring Patient Access to Critical Breakthrough Products Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER NIETO CAREY | — |
| MEGHAN DRENAN | — |
| TODD E GILLENWATER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.